Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The ...

The following is a summary of “High 11-ketotestosterone linked to shorter time to castration resistance in recurrent ...

Castration-resistant prostate cancer (CRPC) is the second most common cause of cancer-related death in men. As tumor cells in patients with CRPC are able to survive under androgen-depletion, there ...

On International Men's Day, the Clinical Trials Arena team investigates three therapies being investigated in prostate cancer ...

Metastatic castration-resistant prostate cancer (mCRPC) is a severe form of late-stage disease where the tumor can no longer ...

DNA testing revolutionizes metastatic castration-resistant prostate cancer prognosis, improving patient outcomes with faster ...

The results come after a prior stumble for the AKT inhibitor class in prostate cancer as Roche last year scrapped development ...

177Lu-PSMA-I&T therapy improved radiographic progression-free survival in metastatic castration-resistant prostate cancer ...

Truqap’s positive clinical data comes after it failed a late-stage study in metastatic triple-negative breast cancer. It ...